Trenbolone Enanthate
Tren E
Long-acting 19-nor injectable; potent androgen with no aromatization. Simple model — peak calibrated.
Key takeaways
- 19-nor veterinary androgen never approved for humans — binds the androgen receptor ~3× stronger than testosterone.
- ~11-day half-life supports twice-weekly injection; 2–3 weeks to steady levels.
- No aromatization, but dyslipidemia, blood pressure, renal stress, and psychological effects are the documented concerns.
- Human PK data essentially does not exist — the curve is a calibrated model, not measured data.
Overview
What it is
Trenbolone enanthate is a long-acting injectable ester of trenbolone, a 19-nor androgen developed for veterinary cattle finishing and never approved for human use. Trenbolone binds the androgen receptor at roughly three times testosterone's affinity and neither aromatizes nor 5-alpha-reduces.
Pharmacokinetics
The enanthate ester gives an ~11-day half-life, which supports twice-weekly injection with a 2–3 week run-up to steady serum levels. Human PK data for trenbolone essentially does not exist, so the curve shown is a simple model calibrated to reported peaks rather than measured human data.
Harm reduction
No aromatization removes estrogenic water retention but not the heavier risks: dyslipidemia, blood-pressure elevation, renal stress, and psychological effects are the well-documented community concerns. HPTA suppression is profound and fast, and hepatotoxicity is rated mild. Monitoring centers on blood pressure, lipids, and kidney markers.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Performance (community) | 150–400 mg weekly | IM | 2× weekly | 8–12 weeks |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 11 days
- Cmax
- 98.5 ng/dL
- Bioavailability
- 71%
- Typical dose
- 150–400 mg
Harm reduction
- Aromatizes
- No
- DHT derivative
- No
- Hepatotoxicity
- mild
- Injection frequency
- 2×/week
⚠ Trenbolone + PDE5 inhibitors (e.g. tadalafil) raises risk of cardiovascular strain and "Tren cough". Monitor closely.
Frequently asked questions
Is trenbolone enanthate approved for humans?
No. Trenbolone is a veterinary compound (cattle implants), and no ester of it carries current human approval anywhere. All human use data is anecdotal, and anything sold for human use is underground-lab product with no quality control.
Acetate vs enanthate — why pick one?
Same hormone, different ester. Enanthate's ~11-day half-life means twice-weekly injection but a slow exit if side effects hit. Acetate clears in ~1.5 days, so problems resolve faster, at the cost of every-other-day or daily injection.
Does trenbolone convert to estrogen?
No — it does not aromatize and is not 5-alpha-reduced. But it does bind the progesterone receptor, so progestogenic effects like gynecomastia can still occur even without any estrogen conversion.
References
- Trenbolone ester PK — Cmax calibrated to ng/dL serum peak.
- Trenbolone ester PK / metabolism study — Source of the ester PK values behind the calibrated curve.
Related articles
Related compounds
Trenbolone Acetate
Short-acting 19-nor ester requiring every-other-day dosing. Simple model — peak calibrated.
Trenbolone Hexahydrobenzylcarbonate
Long-acting trenbolone (original Parabolan). Simple model — peak calibrated.
Testosterone Enanthate
Long-acting testosterone ester; the most common TRT and cycle base. Reaches steady state in ~5 weeks.
Protocols featuring Trenbolone Enanthate
Comments
Loading comments…